Ophthalmic formulations and uses thereof
View Patent ↗Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.
1. A topical ophthalmic formulation comprising:
(a) physiologic levels of magnesium or calcium mimicking physiologic serum levels;
(b) tobramycin or ophthalmically-acceptable salts thereof; and
(c) prednisolone or ophthalmically-acceptable salts thereof; the formulation excluding serum.
2. The formulation of claim 1 wherein (a), (b) and (c) are in a single topical ophthalmic formulation.
3. The formulation of claim 1 comprising tobramycin.
4. The formulation of claim 1 comprising an ophthalmically-acceptable salt of tobramycin.
5. The formulation of claim 1 comprising prednisolone.
6. The formulation of claim 1 comprising an ophthalmically-acceptable salt of prednisolone.
7. The formulation of claim 1 comprising potassium in a concentration from 136.85 to 207.23 mg/L.
8. The formulation of claim 1 comprising:
potassium in a concentration from 136.85 to 207.23 mg/L;
chloride in a concentration from 3368.7 to 3829.68 mg/L;
calcium in a concentration from 85 to 103 mg/L;
magnesium in a concentration from 14.592 to 24.32 mg/L; and
phosphate in a concentration from 85 to 150 mg/L.
9. The formulation of claim 1 comprising:
sodium in a concentration from 3105 to 3358 mg/L;
potassium in a concentration from 136.85 to 207.23 mg/L;
chloride in a concentration from 3368.7 to 3829.68 mg/L;
calcium in a concentration from 85 to 103 mg/L;
magnesium in a concentration from 14.592 to 24.32 mg/L;
phosphate in a concentration from 85 to 150 mg/L; and
bicarbonate in a concentration from 1281 to 2013 mg/L.
10. The formulation of claim 1 further comprising an ophthalmically-acceptable excipient.
11. The formulation of claim 10 wherein the excipient is a buffer, osmotic agent, demulcent, surfactant, emollient, tonicity agent, and/or preservative component.
12. The formulation of claim 11 wherein said preservative component is benzalkonium chloride.
13. The formulation of claim 11 wherein the osmolality of the formulation is from 200 to 500 mOsm/Kg.
14. The formulation of claim 11 wherein the osmolality of the formulation is from 250 to 400 mOsm/Kg.
15. The topical formulation of claim 1 wherein the formulation is an aqueous, non-aqueous, gel, or ointment formulation.
16. A composition for use in a topical ophthalmic formulation comprising:
9 to 11 mg/ml of prednisolone acetate;
2 to 4 mg/ml of tobramycin;
0.25 to 0.30 mg/ml of potassium chloride;
0.28 to 0.35 mg/ml of calcium chloride dihydrate;
0.1 to 0.15 mg/ml of magnesium chloride hexahydrate;
0.1 to 0.2 mg/ml of sodium phosphate dibasic, anhydrous; and
4 to 6 mg/ml of sodium chloride,
the composition excluding serum, the electrolytes in the formulation mimicking a physiologic serum electrolyte concentration of an uninjured eye.
17. The composition of claim 16 further comprising:
2 to 4 mg/ml of hydroxypropyl methylcellulose; and
0.4 to 0.6 mg/ml of Polysorbate 80.
18. The composition of claim 17 further comprising:
4 to 5 mg/ml of sodium borate decahydrate; and
3.5 to 4 mg/ml of sodium sulfate decahydrate.
19. The composition of claim 18 further comprising 0.05 to 0.055 mg/ml of benzalkonium chloride.
20. The topical formulation of claim 1 comprising:
about 10 mg/ml of prednisolone acetate;
about 3 mg/ml of tobramycin;
about 0.275 mg/ml of potassium chloride;
about 0.315 mg/ml of calcium chloride dihydrate;
about 0.125 mg/ml of magnesium chloride hexahydrate;
about 0.15 mg/ml of sodium phosphate dibasic, anhydrous; and
about 5.05 mg/ml of sodium chloride.
21. The topical formulation of claim 20 further comprising:
about 3.0 mg/ml of hydroxypropyl methylcellulose; and
about 0.5 mg/ml of Polysorbate 80.
22. The topical formulation of claim 21 further comprising:
about 4.5 mg/ml of sodium borate decahydrate; and
about 3.8 mg/ml of sodium sulfate decahydrate.
23. The formulation of claim 22 wherein the osmolality of the formulation is from 200 to 500 mOsm/Kg.
24. The formulation of claim 23 wherein the osmolality of the formulation is from 250 to 400 mOsm/Kg.
25. An ophthalmic kit comprising the formulation of claim 1 and a means to apply the formulation to the eye.
26. An ophthalmic kit comprising the composition of claim 16 and a means to apply the composition to the eye.
27. An ophthalmic kit comprising the formulation of claim 20 and a means to apply the formulation to the eye.
28. The kit of claim 25 wherein the application means is an eye dropper, an eye cup, an eye spray or gel ointment tube.
29. The kit of claim 25 further comprising a single dose or a multi dose of the formulation in a single container.
30. A method of treating an ocular disease, injury or disorder comprising administering the formulation of claim 1 to a patient in need of such treatment.
31. The method of claim 30 wherein the ocular disease, injury or disorder is caused by surgery, physical damage to the eye, glaucoma, diabetic retinopathy, and/or macular degeneration.
32. The method of claim 30 wherein the ocular disease, injury or disorder is one which results in vascular leakage in the eye or by inflammation in the eye.
33. The method of claim 32 wherein the inflammation in the eye is caused by surgical trauma, dry eye, an allergic, viral, or bacterial infection, injury from a chemical, radiation or thermal burn, or penetration of a foreign body.
34. A method of treating an eye wherein its normal condition has been disrupted or changed comprising administering to said eye the formulation of claim 1 .
35. A method of treating an eye wherein its normal condition has been disrupted or changed comprising administering to said eye the composition of claim 16 .
36. A method of treating an eye wherein its normal condition has been disrupted or changed comprising administering to said eye the formulation of claim 20 .
37. The topical ophthalmic formulation according to claim 1 , comprising physiologic levels of sodium, potassium, chloride, calcium, magnesium, phosphate, and bicarbonate, and further comprising prednisolone acetate, tobramycin, hydroxypropyl methylcellulose, polysorbate 80, benzalkonium chloride, and a borate buffer.